More Big Pharma Players Have Access Plans For Poorer Countries
GSK Tops Access to Medicine Index Again
Executive Summary
The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.
You may also be interested in...
Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
BioInvent Banks $116m As NHL Drug Nears Phase III
Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.
Need a specific report? 1000+ reports available
Buy Reports